CICC: Maintain outperform rating on Hutchison China MediTech (00013.HK) with a price target of HK$30.

According to the Wise Wealth Financial APP, Zhongjin released a research report stating that it basically maintains its 2025/2026 annual net profit forecast for Wantai Pharmaceutical (00013.HK) at $366 million USD / $35 million USD. The bank maintains an outperform industry rating, based on the DCF model, maintaining a target price of 30 Hong Kong dollars unchanged, with an upside potential of 23.9% compared to the current stock price.